Wolfe Research initiated coverage of Eli Lilly (LLY) with an Outperform rating and $1,000 price target The company has lost over $100B in market cap over the past few weeks, creating an attractive entry point given that “a lot” is not priced into the stock at the moment, the analyst tells investors in a research note. Eli Lilly’s strong share performance in 2025 from GLP-1 volume growth remains underappreciated, and the firm also sees continued manufacturing efficiencies from legacy sites, Wolfe adds.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly initiated with an Outperform at Wolfe Research
- Eli Lilly call volume above normal and directionally bullish
- Eli Lilly announces results from Phase 3 SURMOUNT-1 three-year study
- Market-Beating SCHG ETF: Simple and Effective Exposure to U.S. Growth Stocks
- Needham biotech analysts hold an analyst/industry conference call